December 10, 2002 - ZOLL Announces Health Canada Approval

FOR: ZOLL Medical Corporation

INVESTOR CONTACT: A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
(978) 421-9655
PRESS CONTACT: Robert Minicucci
Corporate Communications Manager
ZOLL Medical Corporation
+1 (978) 421-9832
rminicucci@zoll.com


FOR IMMEDIATE RELEASE
ZOLL Medical Corporation Announces Health Canada Approval

Tuesday, December 10, 2002 – Burlington, MA,- ZOLL Medical Corporation (Nasdaq: ZOLL), a manufacturer of non-invasive cardiac resuscitation devices, which provide pacing and defibrillation, announced today that it has received approval from Health Canada for the AED Plus. This new automated external defibrillator (AED) is the first AED to feature a combination of simple, step-by-step illustrations and audio coaching – making a stressful and challenging medical crisis a more manageable and controlled rescue for laypersons assisting victims of sudden cardiac arrest. The ZOLL AED Plus helps the rescuer more calmly think through the appropriate steps, and administer necessary life-saving treatment as defined by the American Heart Association guidelines.

Richard A. Packer, President and Chief Executive Officer of ZOLL commented, “The approval of the AED Plus for sale in Canada further strengthens our sales efforts. We are pleased with the market acceptance we have achieved in the United States with the AED Plus since its 510k Clearance in March 2002 and we expect the AED Plus to fuel continued growth in our Canadian market.”

The ZOLL AED Plus Product

Time is critical for victims of sudden cardiac arrest – the chance of survival decreases 10 percent every minute defibrillation is delayed. The ZOLL AED Plus is designed to help rescuers respond more rapidly and effectively. The AED Plus is notable for several unique features. It is the first to feature a single electrode pad that is easy to position on the victim’s body (unlike other AEDs which have two pads). It is the first AED to run on off-the-shelf, affordable, consumer batteries. The AED Plus also incorporates ZOLL’s proprietary Rectilinear Biphasic™ waveform, the only biphasic waveform the FDA has cleared and labeled as clinically superior to monophasic defibrillators for conversion of ventricular fibrillation in high-impedance patients and for cardioversion of atrial fibrillation.

The Rapidly Growing First Responder and Public Access Market

The first responder and public access market includes professionals like emergency medical technicians (EMTs), law enforcement and fire personnel, as well as trained laypersons like security guards, health club employees, flight attendants, lifeguards, and office managers.

Frost and Sullivan estimated the AED market to be $173 million dollars in 2001 and estimates an annual growth rate of 28 percent for this market over the next five years, reaching over $600 million in revenues by 2006. The AED market continues to gain momentum with several important developments, including the Occupational Safety and Health Administration (OSHA) endorsement of defibrillator placement in the workplace, the Community Access to Early Defibrillation Act with annual funding for the purchase of defibrillators and related training (which is currently pending approval in Congress), and the enactment of the 1999 Cardiac Arrest Survival Act, mandating all government agencies to establish a plan for placement of defibrillators in Federal buildings.

AEDs are used to treat sudden cardiac arrest resulting from ventricular fibrillation (VF), a spontaneous, mostly fatal interruption of normal heartbeat and a leading cause of death in the United States. The American Heart Association (AHA) estimates that nearly 120,000 of the approximately 300,000 people who die from sudden cardiac arrest could be saved with public access defibrillation. According to the AHA, “Public access defibrillation, which places AEDs in the hands of trained laypersons, has the potential to be the single greatest advance in the treatment of VF cardiac arrest since the development of CPR.”

ZOLL Medical Corporation, headquartered in Burlington, MA, designs, manufactures and markets an integrated line of proprietary, non-invasive resuscitation devices and disposable electrodes. Used by health care professionals to provide both types of cardiac resuscitation – pacing and defibrillation – these products are essential in the emergency treatment of cardiac arrest victims, both inside and outside the hospital. ZOLL also designs and markets software that automates collection and management of both clinical and non-clinical data for emergency medical service providers. ZOLL has operations in the United States, Canada, United Kingdom, Germany, France, the Netherlands, and Australia, and business partners in all of the world’s major markets. For more information about ZOLL and its products, visit the ZOLL web site at www.zoll.com.

Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, the intent, belief or current expectations of ZOLL, its directors or its officers, primarily with respect to ZOLL’s business model and future operating performance of ZOLL, including expectations regarding results in future periods, operating performance and contributions to results from ZOLL’s new Public Access Defibrillation product, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the ZOLL’s Annual Report on Form 10-Q filed on August 14, 2002, the future performance of the direct sales operations, the outcome of a pending patent infringement suit relating to the ZOLL AED Plus, as well as uncertainties regarding the market, acceptance and profitability of the ZOLL AED Plus and M Series CCT, the length and severity of the current economic slowdown and its impact on capital spending budgets, the reduction in overall capital equipment expenditures in the hospital and pre-hospital markets, the potential disruption in the transportation industry on ZOLL’s supply chain and product distribution channels, and the desire or ability of other parties to purchase ZOLL’s products.

###